El tratamiento con sofosbuvir mejora la resistencia a la insulina Inducida por el virus de la hepatitis C

Rey, Esther; Marañón, Patricia; González-Rodríguez, Águeda.
An. R. Acad. Nac. Farm. (Internet) ; 88(número extraordinario): 15-26, diciembre 2022. tab, ilus, graf
Artículo en Español | IBECS (España) | ID: ibc-225738

Documentos relacionados

  1. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
  2. Sofosbuvir Suppresses the Genome Replication of DENV1 in Human Hepatic Huh7 Cells.
  3. Sofosbuvir plus glecaprevir/pibrentasvir as salvage therapy after liver transplantation in NS5A inhibitor-experienced patients. A case series.
  4. A novel fixed-dose combination treatment for chronic hepatitis C, based on NS5A inhibitor fopitasvir and NS5B inhibitor sofosbuvir.
  5. Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study.
  6. Sofosbuvir-based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study.
  7. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
  8. Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.
  9. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.
  10. Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.